TIAA CREF Investment Management LLC grew its holdings in ViewRay, Inc. (NASDAQ:VRAY) by 2,447.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 286,365 shares of the company’s stock after purchasing an additional 275,123 shares during the period. TIAA CREF Investment Management LLC owned approximately 0.50% of ViewRay worth $1,853,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Highbridge Capital Management LLC purchased a new stake in shares of ViewRay in the first quarter valued at $167,000. HighTower Advisors LLC purchased a new stake in shares of ViewRay during the first quarter worth $170,000. White Pine Capital LLC purchased a new stake in shares of ViewRay during the second quarter worth $173,000. Wells Fargo & Company MN purchased a new stake in shares of ViewRay during the first quarter worth $177,000. Finally, UBS Group AG raised its holdings in shares of ViewRay by 447.7% during the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock worth $192,000 after acquiring an additional 18,375 shares in the last quarter. Institutional investors own 53.70% of the company’s stock.
VRAY has been the subject of several recent research reports. Mizuho initiated coverage on ViewRay in a report on Wednesday, September 6th. They set a “buy” rating and a $12.00 price objective for the company. Aegis reiterated a “buy” rating and set a $11.00 price objective on shares of ViewRay in a report on Saturday, July 22nd. Finally, ValuEngine lowered ViewRay from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $10.00.
ViewRay (NASDAQ:VRAY) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.68 million. The company’s quarterly revenue was up 133.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.32) earnings per share.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
What are top analysts saying about ViewRay Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ViewRay Inc. and related companies.